Abstract
Asthma causes a substantial burden of morbidity and mortality, affecting 300 million people worldwide — a figure predicted to increase to 400 million by 2025. Despite the availability of a variety of treatment options and detailed treatment guidelines, many patients with asthma, and in particular those with severe persistent asthma, remain inadequately controlled. Approximately 50–80% of severe asthma has an allergic component, with immunoglobulin E (IgE) playing a role in the underlying allergic inflammatory cascade. Omalizumab is a humanised monoclonal anti-IgE antibody that targets IgE and partially inhibits the inflammatory cascade. Clinical trials have demonstrated that omalizumab added to standard asthma therapy reduces exacerbations and emergency visits with concomitant improvements in asthma control and quality of life in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Add-on omalizumab is indicated for the treatment of patients with inadequately controlled moderate-to-severe (US label) and severe (EU label) persistent allergic asthma despite treatment with high-dose inhaled corticosteroids (and in the EU, high-dose inhaled corticosteroids plus a long-acting β2-agonist). Within this highly-targeted patient population, analyses have been unable to identify pre-treatment clinical characteristics that are predictive of a greater response to omalizumab. In contrast, assessment of response to omalizumab following 16 weeks of treatment appears to be reliably judged by physicians in clinical trial settings and may be a feasible means of selecting patients who should continue treatment.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DP has no shares in pharmaceutical companies. He has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory products: 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough. He has received honoraria for advisory panels with; 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough. He or his research team have received funding for research projects from: 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough, Viatris.
Rights and permissions
About this article
Cite this article
Price, D. The use of omalizumab in asthma. Prim Care Respir J 17, 62–72 (2008). https://doi.org/10.3132/pcrj.2008.00031
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3132/pcrj.2008.00031
This article is cited by
-
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
World Allergy Organization Journal (2018)
-
Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study
BMC Pulmonary Medicine (2016)
-
Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study
Clinical and Molecular Allergy (2015)